DexCom, Inc. (NASDAQ:DXCM) Position Raised by Banco Santander S.A.

Banco Santander S.A. raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 1,839.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 191,959 shares of the medical device company’s stock after buying an additional 182,059 shares during the quarter. Banco Santander S.A.’s holdings in DexCom were worth $14,929,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in DXCM. Farther Finance Advisors LLC lifted its stake in DexCom by 79.1% in the third quarter. Farther Finance Advisors LLC now owns 2,568 shares of the medical device company’s stock valued at $172,000 after buying an additional 1,134 shares during the last quarter. Van ECK Associates Corp lifted its stake in DexCom by 14.0% in the third quarter. Van ECK Associates Corp now owns 20,191 shares of the medical device company’s stock valued at $1,463,000 after buying an additional 2,475 shares during the last quarter. QRG Capital Management Inc. raised its stake in shares of DexCom by 8.6% during the third quarter. QRG Capital Management Inc. now owns 15,697 shares of the medical device company’s stock valued at $1,052,000 after purchasing an additional 1,248 shares in the last quarter. Comprehensive Financial Consultants Institutional Inc. raised its stake in shares of DexCom by 13.5% during the third quarter. Comprehensive Financial Consultants Institutional Inc. now owns 7,334 shares of the medical device company’s stock valued at $492,000 after purchasing an additional 874 shares in the last quarter. Finally, CWA Asset Management Group LLC bought a new stake in shares of DexCom during the third quarter valued at about $222,000. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent analyst reports. Canaccord Genuity Group lifted their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Morgan Stanley lifted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Wells Fargo & Company lifted their price objective on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Trading Down 2.1 %

Shares of DXCM opened at $77.84 on Friday. The business’s 50-day moving average price is $84.83 and its 200 day moving average price is $76.96. The stock has a market capitalization of $30.42 billion, a P/E ratio of 54.43, a P/E/G ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.